TP53 and endometrial cancer: Mutations in TP53 lead to the loss of these regulatory functions and are detected in 20–30% of endometrial cancers; these mutations are associated with aggressive disease features, including high-grade, advanced stage, lymphovascular invasion, nonendometrioid histology, and poor prognosis [43].